$ASTH
Astrana Health, Inc. Stock $asth

$asth Overview Financials Valuation SEC Filings Company Website

2018 Form 10-K Financial Statement

#000114420419014671 Filed on March 18, 2019

Income Statement

Concept	2018	2017 Q4	2017
Revenue	$519.9M	$259.5M	$356.4M
YoY Change	45.9%	1555.52%	709.0%
Cost Of Revenue	$361.1M	$180.4M	$273.5M
YoY Change	32.06%	1318.7%	7.33%
Gross Profit	$158.8M	$79.10M	$82.90M
YoY Change	91.52%	2573.19%	-139.34%
Gross Profit Margin	30.54%	30.48%	23.26%
Selling, General & Admin	$47.20M	$10.20M	$26.20M
YoY Change	80.15%	126.67%	40.86%
% of Gross Profit	29.73%	12.9%	31.6%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$19.30M	$18.77M	$19.08M
YoY Change	1.19%	12502.9%	5.3%
% of Gross Profit	12.16%	23.73%	23.01%
Operating Expenses	$431.5M	$30.60M	$321.2M
YoY Change	34.33%	551.06%	9.16%
Operating Profit	$88.43M	$48.50M	$35.15M
YoY Change	151.61%	-2885.77%	200.69%
Interest Expense	$561.0K	$13.90M	$79.69K
YoY Change	603.99%	138997.37%	29.39%
% of Operating Profit	0.63%	28.66%	0.23%
Other Income/Expense, Net	-$5.805M	$100.0K	$14.57M
YoY Change	-139.86%		103.78%
Pretax Income	$82.63M	$62.60M	$49.71M
YoY Change	66.21%	-4619.99%	163.91%
Income Tax	$22.36M	$13.60M	$3.887M
% Of Pretax Income	27.06%	21.73%	7.82%
Net Earnings	$10.84M	$37.90M	$25.80M
YoY Change	-58.01%	-2287.33%	125.27%
Net Earnings / Revenue	2.08%	14.61%	7.24%
Basic Earnings Per Share	$0.33		$1.01
Diluted Earnings Per Share	$0.29	$389.9K	$0.90
COMMON SHARES
Basic Shares Outstanding	32.89M shares		25.53M shares
Diluted Shares Outstanding	37.91M shares		28.66M shares

Balance Sheet

Concept	2018	2017 Q4	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$108.0M	$100.9M	$100.9M
YoY Change	7.04%	2422.5%	1059.77%
Cash & Equivalents	$106.9M	$99.75M	$99.70M
Short-Term Investments	$1.100M	$1.100M	$1.100M
Other Short-Term Assets	$8.400M	$21.10M	$21.10M
YoY Change	-60.19%	4120.0%	6933.33%
Inventory
Prepaid Expenses
Receivables	$56.50M	$7.603M	$20.10M
Other Receivables	$0.00	$2.000M	$2.000M
Total Short-Term Assets	$172.9M	$144.2M	$144.2M
YoY Change	19.9%	77.63%	867.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.70M	$13.81M	$13.80M
YoY Change	-7.97%	33.17%	1050.0%
Goodwill		$86.20M
YoY Change		-16.64%
Intangibles		$103.5M
YoY Change		-4.22%
Long-Term Investments	$35.30M	$21.90M	$21.90M
YoY Change	61.19%	-9.7%
Other Assets	$2.000M	$1.632M	$2.400M
YoY Change	-16.67%	2.15%	140.0%
Total Long-Term Assets	$340.1M	$346.5M	$346.4M
YoY Change	-1.82%	28.88%	5977.19%
TOTAL ASSETS
Total Short-Term Assets	$172.9M	$144.2M	$144.2M
Total Long-Term Assets	$340.1M	$346.5M	$346.4M
Total Assets	$513.0M	$490.6M	$490.6M
YoY Change	4.57%	40.18%	2281.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.600M	$3.786M	$2.000M
YoY Change	330.0%	165.79%	-74.68%
Accrued Expenses	$5.000M	$21.50M	$21.50M
YoY Change	-76.74%
Deferred Revenue		$250.0K
YoY Change
Short-Term Debt	$0.00	$5.500M	$5.500M
YoY Change	-100.0%	1275.0%	14.58%
Long-Term Debt Due	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	-50.0%	0.0%
Total Short-Term Liabilities	$72.00M	$109.6M	$109.6M
YoY Change	-34.31%	116.49%	655.86%
LONG-TERM LIABILITIES
Long-Term Debt	$13.50M	$600.0K	$600.0K
YoY Change	2150.0%		-88.0%
Other Long-Term Liabilities	$1.200M	$19.20M	$19.20M
YoY Change	-93.75%	2300.0%	2642.86%
Total Long-Term Liabilities	$14.70M	$44.72M	$19.80M
YoY Change	-25.76%	-8.6%	247.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$72.00M	$109.6M	$109.6M
Total Long-Term Liabilities	$14.70M	$44.72M	$19.80M
Total Liabilities	$332.5M	$154.3M	$330.7M
YoY Change	0.54%	1291.93%	1474.76%
SHAREHOLDERS EQUITY
Retained Earnings		$1.735M
YoY Change		-105.24%
Common Stock		$32.31K
YoY Change		435.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$180.5M	$159.9M	$159.9M
YoY Change
Total Liabilities & Shareholders Equity	$513.0M	$490.6M	$490.6M
YoY Change	4.57%	40.18%	2281.55%

Cashflow Statement

Concept	2018	2017 Q4	2017
OPERATING ACTIVITIES
Net Income	$10.84M	$37.90M	$25.80M
YoY Change	-58.01%	-2287.33%	125.27%
Depreciation, Depletion And Amortization	$19.30M	$18.77M	$19.08M
YoY Change	1.19%	12502.9%	5.3%
Cash From Operating Activities	$25.50M	$30.38M	$51.83M
YoY Change	-50.81%	14366.67%	136.54%
INVESTING ACTIVITIES
Capital Expenditures	$1.170M	-$2.020M	$2.085M
YoY Change	-43.88%	3940.0%	-36.95%
Acquisitions	$0.00		$0.00
YoY Change
Other Investing Activities	-$24.01M	$10.06M	$28.80M
YoY Change	-183.37%	-4291.67%	-2742.2%
Cash From Investing Activities	-$25.18M	$8.030M	$26.72M
YoY Change	-194.26%	-2967.86%	-398.28%
FINANCING ACTIVITIES
Cash Dividend Paid	$17.76M		$10.45M
YoY Change	69.97%		-60.81%
Common Stock Issuance & Retirement, Net	$4.847M		$1.015M
YoY Change	377.49%		-109.77%
Debt Paid & Issued, Net	$0.00		$0.00
YoY Change
Cash From Financing Activities	-$11.18M	-15.03M	-$14.98M
YoY Change	-25.37%	-5282.76%	-12.66%
NET CHANGE
Cash From Operating Activities	$25.50M	30.38M	$51.83M
Cash From Investing Activities	-$25.18M	8.030M	$26.72M
Cash From Financing Activities	-$11.18M	-15.03M	-$14.98M
Net Change In Cash	-$10.86M	23.38M	$63.57M
YoY Change	-117.09%	10527.27%	-1617.24%
FREE CASH FLOW
Cash From Operating Activities	$25.50M	$30.38M	$51.83M
Capital Expenditures	$1.170M	-$2.020M	$2.085M
Free Cash Flow	$24.33M	$32.40M	$49.75M
YoY Change	-51.1%	12361.54%	167.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	18005661
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99749199
CY2018Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	118600000
CY2017Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	135300000
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	18000000
CY2017	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	18000000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4300000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	400000
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1127102
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1143095
CY2018Q4	us-gaap	Goodwill Goodwill	185805880
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7734631
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7602812
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8388231
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5144303
CY2018Q4	us-gaap	Assets Current AssetsCurrent	172862792
CY2017Q4	us-gaap	Assets Current AssetsCurrent	144159562
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	86875883
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	103533558
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43353787
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26249532
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19303179
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19075353
CY2017Q4	us-gaap	Assets Assets	490635793
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	361132111
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	273453287
CY2017Q4	us-gaap	Goodwill Goodwill	189847202
CY2018Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	17500000
CY2017Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	15000000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745470
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	745235
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1205962
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1632406
CY2018Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	340136257
CY2017Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	346476231
CY2018Q4	us-gaap	Assets Assets	512999049
CY2018	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	3798866
CY2017	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	2431791
CY2018	us-gaap	Operating Expenses OperatingExpenses	431475590
CY2017	us-gaap	Operating Expenses OperatingExpenses	321209963
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	88432162
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	35145967
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8125285
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1112541
CY2018	us-gaap	Interest Expense InterestExpense	560515
CY2017	us-gaap	Interest Expense InterestExpense	79689
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	1258638
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	1015204
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0
CY1999Q3	ameh	Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement	P30Y
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2017	us-gaap	Net Income Loss NetIncomeLoss	25801842
CY2018	us-gaap	Net Income Loss NetIncomeLoss	10835002
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	20022486
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	49432489
CY2017	us-gaap	Profit Loss ProfitLoss	45824328
CY2018	us-gaap	Profit Loss ProfitLoss	60267491
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	49711113
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	82627131
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14565146
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5805031
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	168102
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1622131
CY2017	us-gaap	Gain Loss On Investments GainLossOnInvestments	13697018
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2017	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	921938
CY2018	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	0
CY2017	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-44886
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106891503
CY2018Q1	ameh	Paymentofrevenue Paymentofrevenue	7300000
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	86627847
CY2017	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	37112775
CY2018	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
CY2017	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-44886
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	51833923
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25496039
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	249193
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	1114332
CY2018Q4	ameh	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash	745220
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	14984000
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets Noncurrent BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent	2498417
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	217241
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	42374500
CY2015Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	5338886
CY2016	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-44886
CY2017	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	5294000
CY2017	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	5294000
CY2017Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	0
CY2018	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	86394383
CY2018	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	6109205
CY2018	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	61092050
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	36367555
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	7261588
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	3211028
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	66648574
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	8632893
CY2018Q4	ameh	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities	39353540
CY2018Q4	ameh	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Line Of Credit BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit	25000
CY2018Q4	ameh	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable	5376215
CY2018Q4	ameh	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable To Related Party BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty	9921938
CY2018Q4	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	3142000
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	66451586
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	196988
CY2018	ameh	Payments For Agreement Termination PaymentsForAgreementTermination	400000
CY2017	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	478873780
CY2017	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	9982706
CY2017	ameh	Business Acquisition Proforma Weighted Average Common Shares Outstanding Basic BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic	25525786
CY2017	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.39
CY2017	ameh	Business Acquisition Proforma Weighted Average Common Shares Outstanding Diluted BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted	28661735
CY2017	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	0.35
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26716009
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25182818
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2084770
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1170064
CY2017	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0
CY2018	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	16706152
CY2017	ameh	Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare	0
CY2018	ameh	Payment Of Investment Privately Held Entity Does Not Report To Nav Per Share PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare	405000
CY2017	ameh	Proceeds On Sale Of Investment Privately Held Entity That Does Not Report Nav Pershare ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare	25000
CY2018	ameh	Proceeds On Sale Of Investment Privately Held Entity That Does Not Report Nav Pershare ProceedsOnSaleOfInvestmentPrivatelyHeldEntityThatDoesNotReportNAVPershare	0
CY2017	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	1240000
CY2018	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	607411
CY2017	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	10000000
CY2018	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	7500000
CY2017	us-gaap	Proceeds From Sale Of Loans Receivable ProceedsFromSaleOfLoansReceivable	200000
CY2018	us-gaap	Proceeds From Sale Of Loans Receivable ProceedsFromSaleOfLoansReceivable	0
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5283
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9013
CY2017	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	-228287
CY2018	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	0
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	388138
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8423366
CY2017	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	5661313
CY2018	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	4134209
CY2017	ameh	Increasedecrease In Capitation Incentives Payable IncreasedecreaseInCapitationIncentivesPayable	1878355
CY2018	ameh	Increasedecrease In Capitation Incentives Payable IncreasedecreaseInCapitationIncentivesPayable	-21500000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3687022
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-22669230
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	220925
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2446
CY2017	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	-1260064
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	263191
CY2018	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	2813564
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4108970
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-20675807
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14000966
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	14480000
CY2017	ameh	Finite Lived Intangible Assets Accumulated Amortization Addition FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition	17500000
CY2017	us-gaap	Gain Loss On Investments GainLossOnInvestments	13697018
CY2018	ameh	Finite Lived Intangible Assets Accumulated Amortization Addition FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition	17100000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1600000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2200000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13814306
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12721082
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11863045
CY2017	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	921938
CY2017	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	86005
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-25005
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2743116
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1441089
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	84882000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	29530000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7793000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9448000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10960000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	12671000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25677351
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26722048
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	250000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9024235
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3004215
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2251741
CY2017Q4	ameh	Subcontractor Ipa Risk Pool Payable SubcontractorIpaRiskPoolPayable	1348376
CY2018Q4	ameh	Subcontractor Ipa Risk Pool Payable SubcontractorIpaRiskPoolPayable	2532750
CY2017Q4	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	547307
CY2018Q4	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	300000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3786381
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4481544
CY2018	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	0
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	57600117
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	132727000
CY2017	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	14984000
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3235000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	40942442
CY2016Q4	us-gaap	Goodwill Goodwill	103407351
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	86439851
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.17
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.078
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.271
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.194
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2390569
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1951238
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8345235
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22359640
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3886785
CY2018Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1886010
CY2017Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1001754
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1660664
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.018
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.019
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.007
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1784524
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.029
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.014
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.001
CY2018	us-gaap	Health Care Organization Expenses Net HealthCareOrganizationExpensesNet	209002961
CY2018	ameh	Operating Loss Carryforwards Limitation Rate On Taxable Income OperatingLossCarryforwardsLimitationRateOnTaxableIncome	0.8
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3400000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	21058703
CY2017Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	6700000
CY2017	ameh	Adjustments For Medical Liabilities AdjustmentsForMedicalLiabilities	-633386
CY2018	ameh	Adjustments For Medical Liabilities AdjustmentsForMedicalLiabilities	-781924
CY2017	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	92476160
CY2018	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	167537480
CY2017	us-gaap	Health Care Organization Expenses Net HealthCareOrganizationExpensesNet	121846375
CY2017	ameh	Effective Income Tax Rate Reconciliation Federal Rate Adjustment EffectiveIncomeTaxRateReconciliationFederalRateAdjustment	-0.097
CY2018	ameh	Effective Income Tax Rate Reconciliation Federal Rate Adjustment EffectiveIncomeTaxRateReconciliationFederalRateAdjustment	0.013
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.044
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.067
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	24916598
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	19615935
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	3385932
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	3395417
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	21530666
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16220518
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	504307
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	792781
CY2017	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	23075516
CY2018	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	36549348
CY2017	ameh	Medical Liabilities Added From Merger MedicalLiabilitiesAddedFromMerger	39353540
CY2018	ameh	Medical Liabilities Added From Merger MedicalLiabilitiesAddedFromMerger	0
CY2016Q4	ameh	Medical Liabilities Current MedicalLiabilitiesCurrent	18957465
CY2017Q4	ameh	Medical Liabilities Current MedicalLiabilitiesCurrent	63972318
CY2017Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	4343341
CY2018Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	4996906
CY2017	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	266000
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	300000
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	225117029
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	172129744
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	34578
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	32305
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	162723051
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	158181192
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17788203
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1734531
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	180545832
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	159948028
CY2018Q4	us-gaap	Minority Interest MinorityInterest	998320
CY2017Q4	us-gaap	Minority Interest MinorityInterest	4235398
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	181544152
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	164183426
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	512999049
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490635793
CY2017	ameh	Restricted Cash Acquired From Acquisition RestrictedCashAcquiredFromAcquisition	18000000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32893940
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	238633
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30704875
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	24556136
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5954666
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-18718113
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2018Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	48721325
CY2017Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	12514492
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling After Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	243000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7117000
CY2017Q3	us-gaap	Capital Leases Contingent Rental Payments Due CapitalLeasesContingentRentalPaymentsDue	9910
CY2017Q3	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.0300
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	19219251
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	9646172
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5336885
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	185130
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	168413
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	282913
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6414256
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7069776
CY2018Q4	ameh	Deferred Tax Assets Liabilities Property Plant And Equipment DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment	-1286087
CY2017Q4	ameh	Deferred Tax Assets Liabilities Property Plant And Equipment DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment	-1286452
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-24084892
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-28626943
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5025000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	25075489
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13279620
CY2018Q4	ameh	Incentive Payable Current IncentivePayableCurrent	0
CY2017Q4	ameh	Incentive Payable Current IncentivePayableCurrent	21500000
CY2018Q4	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	1538598
CY2017Q4	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	2017437
CY2018Q4	ameh	Medical Liabilities Current MedicalLiabilitiesCurrent	33641701
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	11621861
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3198495
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25525786
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37914886
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28661735
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	673878
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	54876
CY2018Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	619002
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	101741
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	517261
CY2018Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	750000
CY2018Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	160714
CY2018Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	589286
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	119000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	119000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	119000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	119000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	119000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	79000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2018	ameh	Antidilutive Securities Excluded From Computation Of Earnings Per Share Shares AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares	1682110
CY2018	ameh	Restricted Cash Acquired From Acquisition RestrictedCashAcquiredFromAcquisition	0
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2018Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	40257
CY2017Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	510391
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	101741
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	98738
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72019647
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109601999
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	19615935
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	24916598
CY2018Q4	ameh	Liability For Unissued Equity Shares Noncurrent LiabilityForUnissuedEquitySharesNoncurrent	1185025
CY2017Q4	ameh	Liability For Unissued Equity Shares Noncurrent LiabilityForUnissuedEquitySharesNoncurrent	1185025
CY2018Q4	ameh	Dividend Payable Noncurrent DividendPayableNoncurrent	0
CY2017Q4	ameh	Dividend Payable Noncurrent DividendPayableNoncurrent	18000000
CY2017Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	619001
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34318221
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	44720624
CY2018Q4	us-gaap	Liabilities Liabilities	106337868
CY2017Q4	us-gaap	Liabilities Liabilities	154322623
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4300000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	2848000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo	2267000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree	783000
CY2018	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	27300
CY2017	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0
CY2018	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	8000000
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5376215
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour	487000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive	489000
CY2017	ameh	Antidilutive Securities Excluded From Computation Of Earnings Per Share Shares AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares	1682110
CY2018Q4	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value Per Share InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare	405000
CY2017Q4	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value Per Share InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare	0
CY2018Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	13000000
CY2017Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000
CY2018	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	10200000
CY2018	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	1400000
CY2018Q4	us-gaap	Fresh Start Adjustment Increase Decrease Deferred Income Tax Liabilities Noncurrent FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent	3200000
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34578040
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32304876
CY2018Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1850603
CY2017Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1682110
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018	us-gaap	Revenues Revenues	519907752
CY2017	us-gaap	Revenues Revenues	356355930
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87587720
CY2017	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1652286
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2059533
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1933588
CY2017	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	5294000
CY2017	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	859430
CY2017	us-gaap	Dividends Dividends	19697923
CY2017	ameh	Stock Issued During Period Value Conversion Of Liability To Equity StockIssuedDuringPeriodValueConversionOfLiabilityToEquity	1237650
CY2017	ameh	Stock Issued During Period Value Merger StockIssuedDuringPeriodValueMerger	64421383
CY2018	ameh	Adjustments To Additional Paid In Capital Business Combination Purchase Consideration AdjustmentsToAdditionalPaidInCapitalBusinessCombinationPurchaseConsideration	-868000
CY2018	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	432113
CY2018	us-gaap	Payments Of Dividends PaymentsOfDividends	17758808
CY2017	us-gaap	Payments Of Dividends PaymentsOfDividends	10447923
CY2017	us-gaap	Interest Paid Net InterestPaidNet	51043
CY2018	ameh	Deferred Tax Liability Adjusted To Goodwill DeferredTaxLiabilityAdjustedToGoodwill	1110456
CY2017	ameh	Deferred Tax Liability Adjusted To Goodwill DeferredTaxLiabilityAdjustedToGoodwill	0
CY2017	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000000
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-9000000
CY2018	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	98735
CY2017	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	102348
CY2018	ameh	Proceeds From Stock Options Exercised Included In Liabilities ProceedsFromStockOptionsExercisedIncludedInLiabilities	0
CY2017	ameh	Proceeds From Stock Options Exercised Included In Liabilities ProceedsFromStockOptionsExercisedIncludedInLiabilities	425025
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3996677
CY2018	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	200
CY2018	us-gaap	Dividends Dividends	1975010
CY2018	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	27500
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	631561
CY2018	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	3996680
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	164797
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2160736
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5047643
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3175836
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11176343
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14975549
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10863122
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	63574383
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107636973
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	23642662
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	24362223
CY2018	us-gaap	Interest Paid Net InterestPaidNet	462336
CY2018	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	65283000
CY2018	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0
CY2017	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	5294000
CY2018	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0
CY2017	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	5376215
CY2018	ameh	Reclassification Of Liability For Unissued Common Shares Payable To Equity ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity	0
CY2017	ameh	Reclassification Of Liability For Unissued Common Shares Payable To Equity ReclassificationOfLiabilityForUnissuedCommonSharesPayableToEquity	1237650
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3798866
CY2018	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	-242456
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Risks</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had major payors that contributed the following percentage of net revenue:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none; border-collapse: collapse; margin: 0in 0in 0in 0.5in; width: 90%;;text-align:left;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For The Years Ended</div></div><br/><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;;width:;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payor A</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14.6</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14.1</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payor B</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18.7</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;">%</td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">18.1</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payor C</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11.1</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payor D</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">14.1</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;">%</td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">11.3</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 74%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;">Payor F</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; text-decoration: none;"> </div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; text-decoration: none;"> </div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;">14.1</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;">%</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; text-decoration: none;"> </div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; margin-bottom: 0px; margin-top: 0px; text-decoration: none;"> </div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 10%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;">%</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; margin-bottom: 0px; margin-top: 0px;"> </div></td><td style="border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; font-size: 10pt;">*      <div style="font-size:10pt;;display:inline;"><div style="font-family:times new roman,times,serif;;display:inline;"> Less than 10% of total net revenues</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had major payors that contributed to the following percentage of gross receivables:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none; border-collapse: collapse; margin: 0in 0in 0in 0.5in; width: 90%;;text-align:left;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December 31,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payor D</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">34.1</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;">%</td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">23.8</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Payor E</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">42.2</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;">%</td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none; margin-bottom: 0px; margin-top: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">30.5</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4	ameh	Allinclusive Population Based Payments To Be Received AllinclusivePopulationBasedPaymentsToBeReceived	5500000
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9100000
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	300000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1124917
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	0
CY2018Q4	ameh	Deferred Tax Assets Investment DeferredTaxAssetsInvestment	884922
CY2018	ameh	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Entity Conversion Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsEntityConversionPercent	0.005
CY2017	ameh	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Entity Conversion Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsEntityConversionPercent	0
CY2018	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	use of the Company's net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change.
CY2017	ameh	Increase Decrease In Deferred Tax Assets Due To Change In Enacted Tax Rate IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate	6600000
CY2017	ameh	Increase Decrease In Deferred Tax Liabilities Due To Change In Enacted Tax Rate IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate	16300000
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	9700000
CY2018	ameh	Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod	151346
CY2018	ameh	Share Based Compensation Arrangement By Share Based Payment Award Cashless Options Exercises In Period Net ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriodNet	109438
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	488464
CY2017	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-6593783
CY2018	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	28363108
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-41784
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1112541
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8125285
CY2018Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	800000
CY2018Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2400000
CY2017	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	39716000
CY2018	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	242456
CY2018	ameh	Goodwill Decrease Merger Transaction Costs GoodwillDecreaseMergerTransactionCosts	914011
CY2018	us-gaap	Goodwill Subsequent Recognition Of Deferred Tax Asset GoodwillSubsequentRecognitionOfDeferredTaxAsset	196445
CY2018	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	671555
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	21903524
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	34876980
CY2017	ameh	Reclassification Of Aps Non Controlling Interest To Equity ReclassificationOfAPSNonControllingInterestToEquity	0
CY2018	ameh	Reclassification Of Aps Non Controlling Interest To Equity ReclassificationOfAPSNonControllingInterestToEquity	2832180
CY2018Q4	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	33100000
CY2018	ameh	Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm	P2Y11M19D
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.93
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3331995
CY2018Q4	ameh	Class Of Warrants Or Right Forfeitures In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue	0
CY2018	ameh	Class Of Warrants Or Right Exercise Price Of Warrants Forfeited In Period ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod	4.50
CY2018	ameh	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	-30189
CY2018Q4	ameh	Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue	3000000
CY2018	ameh	Class Of Warrants Or Right Exercise Price Of Warrants Exercised In Period ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod	7.84
CY2018	ameh	Number Of Warrants Exercised NumberOfWarrantsExercised	-286357
CY2018Q4	ameh	Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue	0
CY2018	ameh	Class Of Warrants Or Right Exercise Price Of Warrants Grant In Period ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod	0
CY2018	ameh	Number Of Warrants Granted NumberOfWarrantsGranted	0
CY2017Q4	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	52000000
CY2017	ameh	Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm	P3Y8M26D
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3648541
CY2017Q4	ameh	Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue	0
CY2017	ameh	Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y
CY2017	ameh	Class Of Warrants Or Right Exercise Price Of Warrants Grant In Period ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod	10.49
CY2017	ameh	Number Of Warrants Granted NumberOfWarrantsGranted	1750000
CY2017Q4	ameh	Class Of Warrants Or Right Assumed Rom Merger Aggregate Intrinsic Value ClassOfWarrantsOrRightAssumedRomMergerAggregateIntrinsicValue	1800000
CY2017	ameh	Class Of Warrant Or Rights Assumed From Merger Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsAssumedFromMergerWeightedAverageRemainingContractualTerm	P2Y8M8D
CY2017	ameh	Number Of Warrants Assumed From Merger NumberOfWarrantsAssumedFromMerger	1898541
CY2016Q4	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	0
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2017	ameh	Non Cash Or Part Non Cash Acquisition Conversion Of Loan Receivable To Investment Interest NonCashOrPartNonCashAcquisitionConversionOfLoanReceivableToInvestmentInterest	0
CY2018	ameh	Non Cash Or Part Non Cash Acquisition Conversion Of Loan Receivable To Investment Interest NonCashOrPartNonCashAcquisitionConversionOfLoanReceivableToInvestmentInterest	5000000
CY2017	ameh	Purchase Price Adjustment For Acceleration Of Vested Stock Options PurchasePriceAdjustmentForAccelerationOfVestedStockOptions	0
CY2018	ameh	Purchase Price Adjustment For Acceleration Of Vested Stock Options PurchasePriceAdjustmentForAccelerationOfVestedStockOptions	868000
CY2017	ameh	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	0
CY2018	ameh	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	-109
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54925712
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118500095
CY2017Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	0
CY2018Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1488313
CY2017	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0
CY2018	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	495134
CY2018	ameh	Adjustments To Adoption Of New Accounting Standard AdjustmentsToAdoptionOfNewAccountingStandard	1002468
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-style: none; border-color: initial; padding: 0px; vertical-align: top; width: 0.3pt;"></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;width: 36pt;"><div style="font-family: "times new roman", serif;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: "times new roman", serif;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Description of Business</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apollo Medical Holdings, Inc. (“ApolloMed”), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the “Merger Agreement”) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, (“Merger Subsidiary”), Network Medical Management, Inc. (“NMM”), and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM (the “Merger”). The Merger closed and became effective on December 8, 2017 (the “Closing”) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and control of the Board of ApolloMed. For accounting purposes, the Merger is treated as a “reverse acquisition” and NMM is considered the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the Closing, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger. Effective as of the Closing, ApolloMed’s board of directors approved a change in ApolloMed’s fiscal year end from March 31 to December 31, to correspond with NMM’s fiscal year end prior to the Merger.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the “Company”) is a physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective manner and serves patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organizations (“HMOs”), with a small portion of </div> the Company’s <div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (“AMM”), APA ACO, Inc. (“APAACO”) and Apollo Care Connect, Inc. (“Apollo Care Connect”), and their consolidated entities.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">NMM was formed in 1994 as a management service organization (“MSO”) for the purposes of providing management services to medical companies and independent practice associations (“IPAs”). The management services cover primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California (“APC”) was incorporated on August 17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various health maintenance organizations (“HMOs”) or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On July 1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a Variable Interest Entity (“VIE”) as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation of the APC Joint Planning Board; therefore APC is consolidated by NMM. As of December 31, 2018 and December 31, 2017, APC had an ownership interest of 4.82% and 4.95% in ApolloMed, respectively.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed on March 25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $625,000 for a 41.59% ownership in CDSC. Due to capital stock changes in 2016, APC’s ownership percentage in CDSC’s capital stock changed to 43.80% and 43.43% on May 31, 2016 and July 31, 2016, respectively. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">APC-LSMA was formed on October 15, 2012 as a designated shareholder professional corporation and Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer of APC and Co-CEO of ApolloMed is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits from all the investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, which includes: The IPA line of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and </div> AHMC International Cancer Center (“ICC”).</div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ICC was formed on September 2, 2010 in the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with organizations such as HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November 15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC 40% of the aggregate issued and outstanding shares of capital stock of ICC for $400,000 in cash. Certain requirements to complete the investment transaction were completed in August 2017 and effective on October 31, 2017, ICC was determined to be a VIE of APC and is consolidated by APC as it was determined that APC is the primary beneficiary of ICC through its power and obligation to absorb losses and rights to receive benefits that could potentially be significant to ICC.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Universal Care Acquisition Partners, LLC (“UCAP”), a 100% owned subsidiary of APC, was formed on June 4, 2014, for the purpose of holding the investment in Universal Care, Inc. (“UCI”).</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">APAACO, jointly owned by NMM and AMM, participates in the next generation accountable care organization model (“NGACO Model”) of the Centers for Medicare & Medicaid Services (“CMS”) as of January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM </div> previously <div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">operated three accountable care organizations (“ACOs”) that participated in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an “all or nothing” basis.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2012, ApolloMed formed an ACO, ApolloMed Accountable Care Organization, Inc. (“ApolloMed ACO”) to participate in the MSSP.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On November 11, 2015, NMM, ACO Acquisition Corporation, and APCN-ACO, A Medical Professional Corp. (“APCN-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on January 8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On December 18, 2016, NMM, ACO Acquisition Corporation #2, and Allied Physicians ACO, LLC (“AP-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December 20, 2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As the Company transitioned to the NGACO Model, patients and physicians with the three ACOs have been transferred to APAACO and all MSSP participation agreements with CMS have been terminated effective December 31, 2017.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH”), a hospitalist company, Southern California Heart Centers (“SCHC”), Bay Area Hospitalist Associates (“BAHA”), a medical corporation, ApolloMed Care Clinic (“ACC”) and AKM Medical Group, Inc. (“AKM”). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA operated a hospitalist, intensivist and post-acute care practice with a presence at three acute care hospitals, one long-term acute care hospital and several skilled nursing facilities. BAHA, ACC and AKM are no longer active to any material extent.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">With the purchase of the remaining membership interests on September 1, 2018, ApolloMed holds 100% ownership interest in Apollo Palliative Services, LLC (“APS”), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC (“BCHC”) and Holistic Care Home Health Agency, Inc. (“HCHHA”) and provides palliative care services. The Company paid $200 for the remaining interests and have appropriately recorded the non-controlling interest amount of $2.8 million in the Company’s shareholder’s equity.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2	ameh	Cost Method Investment Description CostMethodInvestmentDescription	In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented approximately 2.8% ownership.
CY2018Q2	ameh	Warrant Term WarrantTerm	5-year warrant to purchase 270,000 membership interests. A 5-year
CY2018Q4	us-gaap	Loans Receivable Net LoansReceivableNet	5000000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;">The preparation of consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including historical medical loss ratios (“MLR”), and incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and the modified retrospective adjustments recorded at the adoption of ASC 606), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4	us-gaap	Line Of Credit LineOfCredit	5000000
CY2018	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	5000000
CY2018	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; margin-bottom: 0px; margin-top: 0px; text-align: justify; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "times new roman", times, serif; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no material effect on net income, cash flows or total assets. During the year ended December 31, 2018 the Company reclassified certain FFS transaction which were treated as revenue in prior years to cost of services totaling $<div style="letter-spacing: 0px; top: 0px;;display:inline;">1.3</div> million for the year ended December 31, 2017.</div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	286357
CY2018	ameh	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	2200000
CY2017	ameh	Class Of Warrants Or Right Exercise Price Of Warrants Assumed From Merger ClassOfWarrantsOrRightExercisePriceOfWarrantsAssumedFromMerger	9.06
CY2017Q4	us-gaap	Loans Receivable Net LoansReceivableNet	10000000
CY2017Q1	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	The letter of credit expired on December 31, 2018 and is deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.
CY2018Q4	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	The letter of credit expires on December 31, 2019 and is deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.
CY2018	ameh	Percentage Of Managing Responsible Of Health Planship PercentageOfManagingResponsibleOfHealthPlanship	1
CY2018Q4	ameh	Extendable Amount On Credit Facility ExtendableAmountOnCreditFacility	8000000
CY2018	us-gaap	Debt Instrument Interest Rate Basis For Effective Rate DebtInstrumentInterestRateBasisForEffectiveRate	prime rate plus 1%
CY2018Q4	ameh	Advanced For Working Capital AdvancedForWorkingCapital	5000000
CY2018Q2	ameh	Line Of Credit Facility Additional Advances LineOfCreditFacilityAdditionalAdvances	2500000
CY2018Q4	ameh	Line Of Credit Facility Additional Advances LineOfCreditFacilityAdditionalAdvances	5000000
CY2018Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	12500000
CY2017Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	5000000
CY2018Q4	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	10.00
CY2018	ameh	Reclassification Of Dividends Related To Shares Repurchase ReclassificationOfDividendsRelatedToSharesRepurchase	4216202
CY2017	ameh	Reclassification Of Dividends Related To Shares Repurchase ReclassificationOfDividendsRelatedToSharesRepurchase	0
CY2018Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000
CY2018Q4	ameh	Paymentofrevenue Paymentofrevenue	8300000
CY2018	ameh	Stock Issued During Period Shares Merger StockIssuedDuringPeriodSharesMerger	480212
CY2018	ameh	Equity Method Investment Significant Influence Description EquityMethodInvestmentSignificantInfluenceDescription	Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate.
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3400000
CY2018Q4	ameh	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Risk Pool Receivable DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRiskPoolReceivable	-2434573
CY2017Q4	ameh	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Risk Pool Receivable DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRiskPoolReceivable	0
CY2017Q4	ameh	Deferred Tax Assets Investment DeferredTaxAssetsInvestment	-1437061
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	144476000
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	144476000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3887647
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000
CY2018Q4	ameh	Payment Of Revenue Reduce PaymentOfRevenueReduce	5500000
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	508133
CY2017Q4	us-gaap	Share Based Compensation ShareBasedCompensation	800000
CY2018	ameh	Holdback Rate HoldbackRate	0.1
CY2018	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	4200000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P9M
CY2018Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	37593
CY2018Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	16.80
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	631562
CY2018	ameh	Payments To Cms Based For Medical Liabilities PaymentsToCMSBasedForMedicalLiabilities	-34464826
CY2017	ameh	Payments To Cms Based For Medical Liabilities PaymentsToCMSBasedForMedicalLiabilities	0
CY2018	ameh	Percentage Of Financial Guarantee Benchmark Amount PercentageOfFinancialGuaranteeBenchmarkAmount	0.02
CY2018Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	11621861
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	44651502000
CY2017Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	12088655000
CY2018	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	1300000
CY2018	ameh	Risk Pool Settlement RiskPoolSettlement	5900000
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7100000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018Q4	ameh	Billing In Excess Of Costs BillingInExcessOfCosts	34500000
CY2018	ameh	Description Of Percentage On Medical Liabilities Program Recorded DescriptionOfPercentageOnMedicalLiabilitiesProgramRecorded	as APAACO’s NGACO program was new and sufficient claims history was not available, the medical liabilities for the NGACO program were estimated and recorded at 100% of the revenue less actual claims processed for or paid to in-network providers.
CY2018	ameh	Stock Repurchase During Period Value Release Of Hold Back Shares StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares	0
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	Apollo Medical Holdings, Inc.
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001083446
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	670207983
CY2018	dei	Trading Symbol TradingSymbol	AMEH
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35799053
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	ameh	Non Cash Reclassification Of Deferred Tax Liabilities NonCashReclassificationOfDeferredTaxLiabilities	900000

Files In Submission

Name	View Source	Status
0001144204-19-014671-index-headers.html	Edgar Link	pending
0001144204-19-014671-index.html	Edgar Link	pending
0001144204-19-014671.txt	Edgar Link	pending
0001144204-19-014671-xbrl.zip	Edgar Link	pending
ameh-20181231.xml	Edgar Link	completed
ameh-20181231.xsd	Edgar Link	pending
ameh-20181231_cal.xml	Edgar Link	unprocessable
ameh-20181231_def.xml	Edgar Link	unprocessable
ameh-20181231_lab.xml	Edgar Link	unprocessable
ameh-20181231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv515312_10k.htm	Edgar Link	pending
tv515312_ex21-1.htm	Edgar Link	pending
tv515312_ex23-1.htm	Edgar Link	pending
tv515312_ex31-1.htm	Edgar Link	pending
tv515312_ex31-2.htm	Edgar Link	pending
tv515312_ex31-3.htm	Edgar Link	pending
tv515312_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASTH
Astrana Health, Inc. Stock $asth

2018 Form 10-K Financial Statement

#000114420419014671 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH Astrana Health, Inc. Stock $asth

2018 Form 10-K Financial Statement

#000114420419014671 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH
Astrana Health, Inc. Stock $asth